Biotech Leader Devin Blass Joins Longeveron As Chief Technology Officer and Senior VP

Longeveron Inc. is a clinical-stage biotech firm focused on regenerative medicine for severe and ageing-related health conditions. Today, the company announced the appointment of Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. Blass will guide Longeveron’s technological and manufacturing efforts in his new role.

“We are delighted to have Devin join Longeveron at this transformational time in the Company’s evolution. This appointment reinforces Longeveron’s commitment to advancing stem cell therapies as well as appropriately resourcing the Company ahead of a potential Biological License Application (BLA) submission in HLHS, should the ongoing pivotal ELPIS II trial produce positive data,” stated Wa’el Hashad, Chief Executive Officer at Longeveron.

Mr Blass has over 15 years of experience developing and producing advanced therapies. Before joining Longeveron, he served as Senior Vice President of Comprehensive Cell Solutions at the New York Blood Center (NYBC) in 2023, leading its contract development and manufacturing organisation (CDMO) division. He oversaw Technical Operations, Business Development, and Cell Sourcing.

"I am thrilled to join Longeveron as the CTO and SVP of CMC. Longeveron’s commitment to advancing regenerative medicine aligns with my passion for developing innovative therapies. I look forward to contributing to the Company’s mission and driving forward our technological and manufacturing strategies to bring transformative treatments to patients,” said Mr Devin Blass.

Previously, Mr  Blass was Vice President of Technical Operations and Site Head at Talaris Therapeutics, where he managed Technical Operations and Supply Chain. He has also led cell manufacturing operations at Bellicum Pharmaceuticals and directed commercial program manufacturing at Mesoblast. Earlier in his career, Mr Blass worked at MD Anderson Cancer Center, where he helped build infrastructure for HPC and Cord Blood licensure. Mr Blass earned a Bachelor’s degree in Biochemistry from Texas State University.